Sotera Health (NASDAQ:SHC) Stock Price Down 5.9% - Time to Sell?

Key Points

• Q1 beat: Sotera reported revenue of $280.05M (+10% YoY) and EPS of $0.18 (vs. $0.17 consensus) and reaffirmed FY 2026 guidance of $0.93–$1.01 EPS and roughly $1.2B–$1.3B revenue.
• Despite the beat, shares fell 5.9% to about $14.48; the decline coincides with a planned CEO transition and a large insider sale (GTCR sold 10M shares), creating near‑term uncertainty.
• Wall Street sentiment is broadly positive with a "Moderate Buy" average rating and an average price target of $20.67 (several firms target up to $24), implying material upside from current levels.

Shares of Sotera Health Company (NASDAQ:SHC - Get Free Report) traded down 5.9% on Tuesday . The company traded as low as $14.26 and last traded at $14.4750. 1,936,603 shares changed hands during trading, a decline of 23% from the average session volume of 2,505,838 shares. The stock had previously closed at $15.39.

Key Sotera Health News

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Q1 results beat expectations: reported revenue $280.05M (+10% YoY) and EPS $0.18 (vs. consensus $0.17); adjusted EBITDA and adjusted EPS improved, supporting margin expansion and the company’s reaffirmed FY outlook. Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
• Positive Sentiment: Media coverage emphasized the upside reaction to the beats, noting strong top‑line growth and investor interest following the print. Sotera Health Company’s NASDAQ: SHC Q1 CY2026: Beats On Revenue, Stock Soars
• Positive Sentiment: Short‑term momentum commentary highlights strength versus broader Nasdaq futures, suggesting investor focus on the company’s operational beats and improving fundamentals. Sotera Health Momentum Builds Beyond Nasdaq Futures Trends
• Neutral Sentiment: FY 2026 guidance affirmed: company gave EPS range $0.93–$1.01 and revenue target roughly $1.2B–$1.3B. The range overlaps street estimates (consensus ~$0.95 EPS) but is wide, leaving room for interpretation on full‑year visibility. Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook
• Neutral Sentiment: Earnings call transcript and slide deck are available for details on backlog, pricing, and regional trends — useful for investors who want color on margin drivers and organic vs. acquisition growth. Sotera Health Company (SHC) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst write‑ups (Zacks, others) confirm the beat but dig into metric comparisons vs. street estimates and prior year, useful for model adjustments rather than signaling a directional surprise. Sotera Health (SHC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Planned CEO transition announced: Alton Shader (from Viant Medical) to become CEO on May 26, with current CEO Michael Petras moving to Executive Chairman — a managed handoff but a source of near‑term uncertainty around strategic continuity and execution. Sotera Health Announces Leadership Transition

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SHC shares. Piper Sandler raised Sotera Health from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $17.00 to $24.00 in a research report on Friday, January 9th. Wall Street Zen downgraded shares of Sotera Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 11th. Wells Fargo & Company cut Sotera Health to an "overweight" rating in a research report on Thursday, January 8th. Royal Bank Of Canada assumed coverage on shares of Sotera Health in a research report on Thursday, January 8th. They issued an "outperform" rating and a $24.00 price target for the company. Finally, Barclays cut their target price on Sotera Health from $20.00 to $18.00 and set an "overweight" rating for the company in a research note on Tuesday, April 14th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $20.67.

Sotera Health Price Performance

The firm has a 50 day moving average of $15.04 and a two-hundred day moving average of $16.49. The company has a market cap of $4.29 billion, a PE ratio of 55.75 and a beta of 1.82. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 3.66.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.01. Sotera Health had a return on equity of 42.38% and a net margin of 6.70%.The firm had revenue of $280.05 million for the quarter, compared to the consensus estimate of $270.78 million. During the same period in the prior year, the firm earned $0.14 EPS. The firm's revenue was up 10.0% on a year-over-year basis. Sotera Health has set its FY 2026 guidance at 0.930-1.010 EPS. Research analysts predict that Sotera Health Company will post 0.88 earnings per share for the current fiscal year.

Insider Activity

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $15.27, for a total transaction of $152,700,000.00. Following the transaction, the director directly owned 12,735,301 shares in the company, valued at approximately $194,468,046.27. The trade was a 43.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 15.36% of the company's stock.

Hedge Funds Weigh In On Sotera Health

A number of large investors have recently made changes to their positions in SHC. IFP Advisors Inc boosted its stake in Sotera Health by 1,105.6% in the 4th quarter. IFP Advisors Inc now owns 1,495 shares of the company's stock worth $26,000 after purchasing an additional 1,371 shares during the period. Rothschild Investment LLC bought a new stake in Sotera Health during the 4th quarter worth approximately $27,000. Root Financial Partners LLC boosted its holdings in Sotera Health by 217.5% in the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company's stock valued at $30,000 after purchasing an additional 1,455 shares during the period. True Wealth Design LLC grew its position in shares of Sotera Health by 389.3% during the 4th quarter. True Wealth Design LLC now owns 1,830 shares of the company's stock valued at $32,000 after purchasing an additional 1,456 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Sotera Health by 831.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company's stock valued at $37,000 after buying an additional 2,935 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Sotera Health Company Profile

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.